Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.65 |
| ▸ | OTC | P00480 | 1/20 | 0.49 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.48 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.48 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.48 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.46 |
| ▸ | NOS2 | P35228 | 5/20 | 0.44 |
| ▸ | NOS3 | P29474 | 3/20 | 0.44 |
| ▸ | NOS1 | P29475 | 3/20 | 0.44 |
| ▸ | ARG2 | P78540 | 4/20 | 0.42 |
| ▸ | ARG1 | P05089 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL27968247 | 1.00 | GSR (0.65) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL2143365 | 1.00 | GSR (0.65) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL292022 | 1.00 | GSR (0.65) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL301606 | 1.00 | GSR (0.65) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL8957537 | 1.00 | GSR (0.65) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL11660904 | 1.00 | GSR (0.65) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL4954180 | 1.00 | GSR (0.65) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL15022773 | 1.00 | GSR (0.65) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL3516723 | 1.00 | GSR (0.65) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL27641260 | 1.00 | GSR (0.65) | GSROTCGNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150140139-A1 | COMPOSITION FOR IMPROVING OR PROMOTING HAIR GROWTH CONTAINING, AS ACTIVE INGREDIENTS, PHOTOSENSITIZER IRRADIATED WITH LIGHT AND PEPTIDE, AND METHOD USING SAME | UNIQUE MEDICARE CO., LTD. (KR) | 2015-05-21 | — | — | US | claimed |
| US-9724416-B2 | Composition for improving or promoting hair growth containing, as active ingredients, photosensitizer irradiated with light and peptide, and method using same | UNIQUE MEDICARE CO., LTD. (KR) | 2017-08-08 | — | — | US | disclosed |
| US-20150140139-A1 | COMPOSITION FOR IMPROVING OR PROMOTING HAIR GROWTH CONTAINING, AS ACTIVE INGREDIENTS, PHOTOSENSITIZER IRRADIATED WITH LIGHT AND PEPTIDE, AND METHOD USING SAME | UNIQUE MEDICARE CO., LTD. (KR) | 2015-05-21 | — | — | US | disclosed |
| CN-104144699-A | INFLUENZA H5 VACCINES | BOEHRINGER INGELHEIM VETMED | 2014-11-12 | — | — | CN | disclosed |
| CN-101553248-B | Novel H5 proteins, nucleic acid encoding same and vectors, and their medicinal use | BOEHRINGER INGELHEIM VETMED | 2012-09-19 | — | — | CN | disclosed |
| CN-102406932-A | Use of vaccines for the treatment/prevention of transmission of influenza pathogens between species | BOEHRINGER INGELHEIM VETMED | 2012-04-11 | — | — | CN | disclosed |
| US-20120052057-A9 | METHOD FOR SELECTING RESPONDERS TO BLOCKADE OF INTEGRIN RECEPTORS | BIOTIE THERAPIES CORPORATION (FI) | 2012-03-01 | — | — | US | disclosed |
| US-8034353-B2 | Peptide vaccine for inducing the production of anti-amyloid β-peptide antibody | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 2011-10-11 | — | — | US | disclosed |
| US-20110150859-A1 | METHOD FOR SELECTING RESPONDERS TO BLOCKADE OF INTEGRIN RECEPTORS | BIOTIE THERAPIES CORPORATION (FI) | 2011-06-23 | — | — | US | disclosed |
| US-20100280229-A1 | POLYPEPTIDE | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 2010-11-04 | — | — | US | disclosed |
| US-20030012780-A1 | Anti-inflammatory medicaments | KAROLINSKA INNOVATION AB | 2003-01-16 | — | — | US | disclosed |
| CN-1262688-A | Integrin binding peptides and uses thereof | BAIAUTAI TREAT CO LTD (FI) | 2000-08-09 | — | — | CN | disclosed |
| US-6096707-A | CYCLIC OLIGO/POLYPEPTIDE INCLUDING AN ARGININE-LYSINE-LYSINE-HISTIDINE SEQUENCE EFFECTIVE TO INHIBIT INTEGRIN-DEPENDENT CELL MIGRATION | BIOTIE THERAPIES LTD. (FI) | 2000-08-01 | — | — | US | disclosed |
| US-6096707-A | CYCLIC OLIGO/POLYPEPTIDE INCLUDING AN ARGININE-LYSINE-LYSINE-HISTIDINE SEQUENCE EFFECTIVE TO INHIBIT INTEGRIN-DEPENDENT CELL MIGRATION | BIOTIE THERAPIES LTD. (FI) | 2000-08-01 | — | — | US | disclosed |
| EP-0994898-A1 | INTEGRIN BINDING PEPTIDE AND USE THEREOF | Biotie Therapies Ltd. (FI) | 2000-04-26 | — | — | EP | disclosed |
| EP-0994898-A1 | INTEGRIN BINDING PEPTIDE AND USE THEREOF | Biotie Therapies Ltd. (FI) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999002551-A1 | INTEGRIN BINDING PEPTIDE AND USE THEREOF | BIOTIE THERAPIES LTD. (FI) | 1999-01-21 | — | — | WO | disclosed |
| WO-1999002551-A1 | INTEGRIN BINDING PEPTIDE AND USE THEREOF | BIOTIE THERAPIES LTD. (FI) | 1999-01-21 | — | — | WO | disclosed |
| EP-0119247-A1 | PRODUCTION OF MATURE PROTEINS IN TRANSFORMED YEAST | IMMUNO NUCLEAR CORPORATION (US) | 1984-09-26 | — | — | EP | disclosed |
| WO-1984001173-A1 | PRODUCTION OF MATURE PROTEINS IN TRANSFORMED YEAST | IMMUNO NUCLEAR CORP (US) | 1984-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150140139-A1 | COMPOSITION FOR IMPROVING OR PROMOTING HAIR GROWTH CONTAINING, AS ACTIVE INGREDIENTS, PHOTOSENSITIZER IRRADIATED WITH LIGHT AND PEPTIDE, AND METHOD USING SAME | TYR, LNPEP, MET | GSR 1129/4885OTC 1006/4885GNAI3 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.